Information Provided By:
Fly News Breaks for August 25, 2015
ABCO
Aug 25, 2015 | 08:36 EDT
Oppenheimer believes that the recent weakness in The Advisory Board has created "a great entry point." The firm says that the execution of the company's recently acquired Royall unit will probably negatively impact The Advisory Board's results. However, the firm thinks that the company's core healthcare segment, which it says accounts for 80% of the company's revenues, "is doing very well." Oppenheimer keeps a $61 price target and Outperform rating on the shares.
News For ABCO From the Last 2 Days
There are no results for your query ABCO